ViGeneron_Logo_NEW.png
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
April 26, 2022 03:00 ET | ViGeneron GmbH
The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ...
ViGeneron_Logo_NEW.png
ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
April 06, 2022 03:00 ET | ViGeneron GmbH
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy productViGeneron is...
ViGeneron_Logo_NEW.png
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
January 18, 2021 02:00 ET | ViGeneron GmbH
MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV)...
ViGeneron_Logo_NEW.png
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
January 05, 2021 02:00 ET | ViGeneron GmbH
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...
Vigeneron_Logo.png
ViGeneron announces closing of series A financing to drive development of next generation gene therapy pipeline
November 28, 2019 02:00 ET | ViGeneron GmbH
Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms Round attracts two esteemed investors - WuXi AppTec and Sequoia Capital China known...